Navigation Links
Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
Date:4/30/2010

the treatment of patients with bipolar disorder discussed in this press release, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets, including the market for RG2417 or other forms of uridine, and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.


'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
2. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
3. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
6. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
9. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
10. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... June 1 DURECT Corporation (Nasdaq: DRRX ) announced today that ... the Jefferies Global Life Sciences Conference on Thursday, June 10 at ... Hotel in New York .   , ...   http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) , , , ...
... , June 1 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... Officer, will present at the Jefferies 2010 Global Life Sciences Conference on ... the Grand Hyatt Hotel in New York, NY . , ... A live webcast of the presentation may be accessed ...
Cached Medicine Technology:DURECT to Present at the Jefferies Global Life Sciences Conference 2
(Date:7/9/2014)... winning is one of the key determinants that makes organized ... mental bonuses ranked near the bottom of 81 determinants of ... fun factors, according to a new study. Despite the common ... the "fun" factor, very little research had been done to ... now. , The results of this study might help researchers ...
(Date:7/9/2014)... School of Medicine at the University of Pennsylvania in ... an $8 million grant from the National Cancer Institute ... (PDT) in patients with malignant pleural mesothelioma, a rare, ... in the lining of the lungs and is caused ... fund a clinical trial and additional studies looking at ...
(Date:7/9/2014)... research into the metabolism of stromal support cells and ... of these cell types in the development of diseases ... conditions and cancer. That was the conclusion of a ... in the leading journal Nature . , Prof. ... wake-up call. The metabolism of cancer cells has been ...
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
(Date:7/9/2014)... more than watching World Cup highlights, Brian Williams refreshing ... in unfortunate positions on railings. A University of Colorado ... Journal shows that YouTube also allows researchers, journals, ... on topics of skin cancer and prevention. , "No ... future of how we communicate around the world," says ...
Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
... by Dr. Agarwal Hospital:, An eye surgeon / scientist ... wide had thought we were 10 years away from,making DNA, ... the making of DNA and used it on her patients ... attributes the Science of Sri Vidya to this,phenomenal discovery. A ...
... fossil hunter and anatomy professor Kenneth Rose, Ph.D. was displaying ... seminar at the Johns Hopkins University School of Medicine when ... , That unanticipated eureka moment has led researchers at the ... rabbits. The fossil evidence in hand, found in west-central India, ...
... an estimated 10 to 13 percent of the American diet. ... in 2007 was $70.5 billion, with estimates for 2008 rising ... into the United States of imported food and food-related products ... which include ports, border crossings, and postal facilities. ...
... Plans for Growth, LAS VEGAS, March 19 ... members of its executive team presented,at the annual Citi ... on Wednesday, March 19, 2008., In addressing the ... and CEO Stephen Hughes recounted the accomplishments of,2007 and ...
... increase risk and may be early indication, study ... A combination of cholesterol-associated gene variants can increase ... sudden cardiac death, Massachusetts General Hospital researchers report. ... for these gene variants in order to identify ...
... than with freshly stored units, study finds , , ... get transfusions of blood that has been stored for ... get newer blood, a new study shows. , In-hospital ... were higher for those getting older blood, conclude physicians ...
Cached Medicine News:Health News:Science of Sri Vidya Benefits DNA Genesis, Says Dr. Sunita Rana Agarwal 2Health News:Good luck indeed: 53 million-year-old rabbit's foot bones found 2Health News:Smart Balance Presented at Citi Small/Midcap Conference 2Health News:Gene Variants Can Predict Threat of Heart Disease 2Health News:Transfusions of 'Older' Blood Don't Work as Well 2Health News:Transfusions of 'Older' Blood Don't Work as Well 3
... Sunglasses collection benefits from innovative research in ... sectors such as the aerospace and automotive ... field and the footwear and textile industry. ... reinvented in the Carrera sunglasses collection to ...
Bottega Venetas new collection expresses a unique style and determined personality: discreet elegance and refined luxury are the themes that inspire the creation of these new models, destined to beco...
The new Stella McCartney sunglasses collection seduces with its sensual appeal and vintage spirit.,Bold patterned finishes, glamourous colour combinations and intricate details make the designers,cre...
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
Medicine Products: